A first aspect of the invention relates to an installation for producing protein-based bioartificial constructs, such as collagen-based and/or fibrin-based constructs, by means of a rotary process using an outer shell and an inner mold, said outer shell having bores and said inner mold being formed in at least two parts. Another aspect of the invention relates to a method for producing protein-based bioartificial constructs, in particular collagen- and/or fibrin-based bioartificial constructs, using the installation according to the invention and to such bioartificial constructs which can be obtained using the method according to the invention. The invention also relates to a device for producing the bioartificial constructs with the aid of the installation according to the invention and finally to a fibrinogen solution which is suitable in particular for the bioartificial construct production process according to the invention.
The invention provides a compound, for use as single compound or for use as a combination of at least two compounds, for use in the prevention and/or treatment of liver fibrosis and/or liver cirrhosis, e.g. as a pharmaceutically active compound for use in the prevention or treatment of liver fibrosis, which compound is an inhibitor of hyaluronan synthetase, or an inhibitor of integrin alpha-6.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
3.
FUSION PROTEIN FOR MAINTENANCE OF REGULATORY T-CELLS
The present invention relates to a fusion protein that provides for maintenance of regulatory T-cells that are polyclonal, e.g. natural isolated antigen-specific Treg cells, and/or Treg cells generated by introduction of a nucleic acid construct for expression of FOXP3, and/or Treg cells which express a chimeric antigen receptor (CAR), which Treg cells in contact with the cognate antigen are activated for suppressive activity, as well as to Treg cells that express the fusion protein, wherein the Treg cells are polyclonal or the Treg cells express a CAR. The fusion protein comprises or consists of an optional secretory leader peptide, IL-2, preferably a linker peptide, and a membrane-spanning anchor, which fusion protein is also termed membrane-bound IL-2.
The new alpharetrovirus-based particles are suitable for high efficiency of transiently transducing animal cells. e.g. human or murine cells, and which efficiently introduce coding and non-coding RNA contained in the alpharetrovirus-based particles into target cells The alpharetrovirus-based particles also provide for high efficiency of the activity and/or integrity of the RNA that is introduced into the animal cells, as the particles protect the incoming RNA from degradation during entry. The transferred RNA can be of non-coding nature (e.g. single guide (sg) RNA. short-hairpin (sh) RNA. micro RNA. or long non-coding (Inc) RNA. or the RNA may encode proteins or peptides. e.g. receptors. transcription factors. cellular enzymes, antigens for use in vaccination, gene/protein therapy and/or gene editing nucleases, recombinases and transposases.
HUMAN MESENCHYMAL STEM CELL-CONDITIONED MEDIUM AND HUMAN MESENCHYMAL STEM CELLS FOR USE IN TREATMENT OF CHRONIC HEART-LUNG AND VASCULAR DISEASES, IN PARTICULAR, OF PULMONARY ARTERIAL HYPERTENSION (PAH)
The present invention relates to the field of medical treatment of chronic disease with stem-cell derived products, in particular, human mesenchymal stem cell-derived treatment of chronic heart-lung and vascular diseases. The inventors provide human mesenchymal stem cell-conditioned medium, such as human umbilical cord mesenchymal stem cell-conditioned medium (HUMSC-CM) for use in treatment of chronic heart-lung and vascular diseases, in particular, pulmonary hypertension (PH, groups 1-5), such as pulmonary arterial hypertension (PAH: group 1 PH according to World Symposium on Pulmonary Hypertension 2018). The invention also provides a method of treating chronic heart-lung-vascular diseases by means of administering such conditioned medium intravascularly. Optionally, the treatment may additionally comprise administering human umbilical cord mesenchymal stem cells to the patient.
Viral vectors based on adeno-associated virus (AAV), preferably AAV serotype 1 (AAV1), are provided for use in transduction of adipocytes. The viral vectors of the invention have the advantage of being adapted in tropism for adipocytes, wherein the viral vectors especially in use for intraperitoneal administration are optimized for adipocytes residing in SCAT (subcutaneous adipose tissue) or in VAT (visceral adipose tissue), or the viral vectors in use for oral administration are optimized for adipocytes residing in SCAT or in VAT.
The invention provides an analytical method for detecting the level of activity of superoxide dismutase (SOD2, e.g. UniProtKB P04179 (SODM_HUMAN) and/or of UBR1 and/or of UBR2 in a sample originating from a patient for determining the sensitivity for, or resistance against, tumour treatment with L-asparaginase.
A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
8.
PATIENT-SPECIFIC IMPLANT AND METHOD FOR ITS MANUFACTURE
The invention relates to a patient-specific implant (5) for insertion into a body cavity of a patient, for example into the round window niche of the middle ear. The invention also relates to a method of manufacturing such an implant (5).
The present invention generally relates to the field of recombinant gene expression in host cells. In particular, the invention relates to a recombinant human myeloid-derived growth factor (MYDGF) protein that exhibits a minimal degree of degradation upon expression in a host cell. The recombinant protein is therefore highly suitable for medical use, in particular for treating heart tissue damage and preventing cell death in myocardial tissue. The invention also provides a nucleic acid which encodes the recombinant protein and a host cell that expresses the recombinant protein. The invention also provides a method for producing the recombinant protein in a host cell.
FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Germany)
Inventor
Schambach, Axel
Vollmer Barbosa, Philippe
Schwarzer, Adrian
Braun, Armin
Abstract
The present invention relates to the field of oligonucleotide-based antiviral therapies. In particular, the invention discloses oligonucleotide molecules that may either be provided as RNA molecules capable of inducing RNAi-mediated immunity against human parainfluenza virus or as antisense oligonucleotides (ASOs), e.g., gapmers, targeting RNAs derived from human parainfluenza virus as well as oligonucleotide-based therapeutics utilizing said oligonucleotide molecules. In further aspects, the invention provides methods for screening and preparing an oligonucleotide-based therapeutic that can be used to treat an infection with a respiratory virus of interest. Such therapeutics can deliver the claimed oligonucleotides, e.g., via LNPs (lipid nanoparticles) or lipid anchors, or via lentiviral vectors or polymers such as, e.g., polyethylenimine (PEI vectors). Finally, the present invention provides a composition for use in treating a respiratory disease which comprises a lentiviral vector pseudotyped with a vesiculoviral envelope glycoprotein and at least one surface protein of influenza A virus and/or of respiratory syncytial virus.
The invention relates to a suction-flushing-system for a medical instrument having at least one optical device in a distal region adapted for insertion into a patient, which is cleanable by means of the suction-flushing-system. The invention also relates to a medical instrument having such a suction-flushing-system.
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/015 - Control of fluid supply or evacuation
The invention provides a viral vector based on adeno-associated virus serotype 2 (AAV2,) which preferentially targets and transduces activated cardiac fibroblasts in vivo, the viral vector comprising a nucleic acid construct for an effector molecule as a transgene, the viral vector being characterized by comprising a capsid protein (CAP) which C-terminally and directly adjacent to amino acid No. 587 of the wild-type amino acid sequence of CAP contains an inserted amino acid section.
The present invention relates to a CAR and to regulatory T-cells (Treg) expressing the CAR for use in the treatment of multiple sclerosis (MS) and/or Alzheimers disease (AD). The CAR, especially Treg expressing the CAR, are suitable for suppressing adverse immune reactions occurring in MS and/or AD due to the high specificity of the CAR for myelin basic protein (MBP) or myelin oligodendrocyte glycoprotein (MOG), which are primary targets of autoimmune reactions in MS and AD.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
14.
CARDIAC ORGANOID WITH INNER PART HAVING CAVITIES AND MULTIPLE LAYERS
A cardiac organoid has a first layer that forms an inner part and has cavities. The first layer is at least in part surrounded by a second layer including endothelial cells and cardiomyocytes. The second layer is at least in part surrounded by a third layer including cardiomyocytes and epicardial cells. The third layer is at least in part surrounded by a fourth layer including fibroblast cells.
The invention relates to a medical insertion system with an insertion device for inserting a medical device attached to the insertion device into a body region of a patient, wherein the insertion device has at least one force sensor for detecting a force transmitted from the medical device to the insertion device in a measuring direction, the insertion system having an evaluation unit for evaluating a force signal which is emitted by the force sensor and represents the force detected by the force sensor.
The present invention pertains to a polypeptide comprising the amino acid sequence according to SEQ ID NO: 1 or a variant or fragment thereof for use in treating or preventing heart failure, myocardial infarction or hypertrophy, reducing infarct size or scar size after myocardial infarction, inducing endothelial cell sprouting after myocardial infarction, protecting cells from ischemia- or reperfusion-induced injury, promoting angiogenesis after myocardial infarction, promoting coronary endothelial cell migration and proliferation, inhibiting cardiomyocyte hypertrophy, or inhibiting inflammation. The present invention further provides a nucleic acid sequence encoding the polypeptide, vectors comprising the nucleic acid sequence, host cells comprising the nucleic acid or vector, and respective pharmaceutical compositions for the same use.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A chimeric antigen receptor (CAR), a cell (particularly an immune cell such as a regulatory T cell) expressing said CAR, a nucleic acid or vector encoding said CAR and various uses of said CAR, cell, nucleic acid or vector is disclosed herein. Particularly, a chimeric antigen receptor (CAR) comprising an antigen recognition domain that specifically binds to ENTPD3, is provided.
The present invention relates to a CAR and to regulatory T-cells (Treg) expressing the CAR, especially for use in the treatment, especially for suppression, of adverse immune reactions against liver tissue, e.g. for use in the treatment of host-versus-graft disease (HvG) against a liver transplant, for use in the treatment of an autoimmune disease directed against liver tissue, or for use in the treatment of inflammatory liver disorder. The invention provides a chimeric antigen receptor (CAR) that comprises an scFv portion, which is specific for the asialoglycoprotein receptor (ASGPR).
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
19.
FUSION PROTEIN FOR LOCALIZED ACTIVATION OF T-CELLS
The invention provides a fusion protein and a nucleic acid construct encoding the fusion protein, preferably an oncolytic viral particle that contains the nucleic acid construct encoding the fusion protein, wherein the fusion protein from N-terminus to C-terminus comprises or consists of a secretory leader peptide - anti-CD3-antibody section - hinge - HIV-Tat.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A chimeric antigen receptor (CAR), a cell (particularly an immune cell such as a regulatory T cell) expressing said CAR, a nucleic acid or vector encoding said CAR and various uses of said CAR, cell, nucleic acid or vector is disclosed herein. Particularly, a chimeric antigen receptor (CAR) comprising an antigen recognition domain that specifically binds to GLP1R is provided.
The present invention relates to the field of gene therapy for the treatment of sensorineural hearing loss. In particular, the invention discloses a composition comprising a 3rd generation lentiviral vector pseudotyped with a viral envelope glycoprotein capable of binding to a receptor expressed in a cell of the inner ear for use in the treatment or prevention of sensorineural hearing loss, wherein said composition has a viral titer of at least 107 TU/mL and is administered to the inner ear of a subject suffering from or in danger to undergo sensorineural hearing loss. The viral envelope glycoprotein is capable of binding to a receptor selected from the group consisting of the LDL-receptor and LDL-R family members, the SLC1 A5-receptor, the Pit1/2-receptor and the PIRYV-G-receptor. Preferably, the viral glycoprotein is MARAV-G, COCV-G, VSV-G, VSV-G ts or PIRYV-G, most preferably, MARAV-G. The lentiviral vector further comprises a cargo sequence comprising, e.g. a protein-coding gene, a miRNA, an shRNA, a lncRNA or an sgRNA, wherein expression of said cargo sequence in the cell of the inner ear is capable of reducing, eliminating or preventing at least a symptom of sensorineural hearing loss in the subject. The invention further discloses a method for treating sensorineural hearing loss in a subject in need thereof.
The present invention relates to a pharmaceutical composition comprising a compound promoting the expression and/or the activity of the non-coding RNA (ncRNA) of SEQ ID NO: 1 or a sequence being at least 85% identical thereto.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention relates to adeno-associated virus capsid polypeptide sequences and their use in therapeutic transgene delivery to the eye and potentially other tissues.
A chimeric antigen receptor (CAR), a cell (particularly an immune cell such as a regulatory T cell) expressing said CAR, a nucleic acid or vector encoding said CAR and various uses of said CAR, cell, nucleic acid or vector is disclosed herein. Particularly, a chimeric antigen receptor (CAR) comprising an antigen recognition domain that specifically binds to DGCR2 is provided.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH (Germany)
MEDIZINISCHE HOCHSCHULE HANNOVER (Germany)
Inventor
Brönstrup, Mark
Messerle, Martin
Arisetti, Nanaji
Kalverkamp, Simon
Korotkov, Vadim
Nahrevanian, Shahab
Orth, Till
Rückert, Jessica
Schultz, Thomas F.
Stephen, Steffi
Wagner, Karen
Abstract
The present invention relates to novel inhibitors of Cytomegalovirus (CMV) of formula (I), wherein Cy is an optionally substituted 1,4 diazepane group; Ar1is an optionally substituted phenyl group; an optionally substituted naphthyl group; or an optionally substituted heteroaryl group containing 5 to 10 ring atoms selected from C, N, O and S; and Ar2 is an optionally substituted heteroaryl group containing 5 or 6 ring atoms selected from C, N, O and S; or a salt thereof.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 31/22 - Antivirals for DNA viruses for herpes viruses
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Adenovirus for use in anti-tumour therapy which has specificity for tumour cells, especially for tumour cells that have reduced activity levels of the tumour suppressor p53. It is known that the majority of tumours characteristically exhibit reduced activity of the tumour repressor p53. In tumour-bearing patients, the adenovirus provides for an effective cross-presentation of tumour antigens, which can be neoantigens. e.g. having low immunogenicity, and hence supports the induction of tumour-specific immune cells, especially of tumour-specific CD8 T− cells. Further, the adenovirus in tumour patients stimulates the non-specific immune response by NK-cells, preferably both locally and systemically, and the adenovirus improves migration of immune cells. e.g. T-cells. NK-cells, and antigen-presenting cells (APC), e.g. dendritic cells, into the tumour, and the adenovirus improves the maturation of immune cells, especially of APC, and improves the cytolysis of tumour cells by immune cells. The adenovirus has an E4 protein which contains an E4 orf4-encoded protein of one of amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.
A chimeric antigen receptor (CAR), a cell (particularly an immune cell such as a regulatory T cell) expressing said CAR, a nucleic acid or vector encoding said CAR and various uses of said CAR, cell, nucleic acid or vector is disclosed herein. Particularly, a chimeric antigen receptor (CAR) comprising an antigen recognition domain that specifically binds to ENTPD3, is provided.
A device for interacting with hearing capabilities of a patient is disclosed. Said device comprising a control unit (11), at least one electrode (1) adapted to stimulate nerves of the patient contactable to the control unit (11), wherein the control unit (11) is adapted to electrically stimulate at least one auditory nerve of the patient; and an acoustic loudspeaker (2) connectable to the control unit (11). The device is adapted to acoustically stimulate at least one of the ear of the patient by emitting acoustic sound with the loudspeaker (2) for acoustic masking, and to electrically stimulate at least one nerve of the patient based on the acoustic masking. At least one of the at least one electrode (1) is adapted to be placed on the outer skin of the head of the patient, wherein the control unit (11) is adapted to stimulate an auditory nerve of the patient and/or a vagus nerve and/or a vestibular nerve and/or a trigeminal nerve, when this at least one electrode (1) is placed on the outer skin of the head of the patient. Another option suggests that at least one electrode (1) of the at least one electrode (1) is adapted to be placed in the inner ear of the patient, in particular in the inner channel and/or in the promontory and/or the around window niche, wherein the control unit (11) is adapted to stimulate a facial nerve and/or a vagus nerve and/or a vestibular nerve and/or a trigeminal nerve, when this at least one electrode (1) is placed in the inner ear of the patient.
The invention relates to a positioning device for positioning a medical instrument relative to a patient, wherein the positioning device has a patient fastening member which is specified to fasten the positioning device to the patient, and has an instrument holder which is specified to hold the medical instrument, wherein the patient fastening member has a patient holding surface for bearing on the patient.
A61B 17/00 - Surgical instruments, devices or methods
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
30.
NEURAL STIMULATION AND SENSING SYSTEM FOR AUDITORY AND NON-AUDITORY ACTIVATION
MED-EL ELEKTROMEDIZINISCHE GERAATE GESELLSCHAFT M.B.H. (Austria)
UNIVERSITY OF UTAH (USA)
FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (USA)
Inventor
Leber, Moritz Michael
Franklin Iv, Robert Kyle
Negi, Sandeep
Crew, Joseph David
Liu, Janet
Ngo, Vinh Quang
Lim, Hubert Hyoungil
Ghose, Geoffrey Mohon
Johnson, Luke Aaron
Sondh, Inderbir Singh
Heiller, Abigail Paige
Adams, Meredith Evelyn
Oxenham, Andrew John
Lenarz, Thomas Heinrich Robert
Dyballa, Karl-Heinz Hiro
Vazquez, Waldo Nogueira
Samii, Amir
Hübner, Keno H.B.
Pontiller, Paul
Eder, Marco
Sieber, Daniel M.
Mayr, Alexander
Wyzisk, Guntram
Hansen, Elisabeth A.
Hammerer, Dominik
Solzbacher, Florian
Rieth, Loren Wellington
Abstract
The present disclosure generally relates to auditory nerve stimulation to create the perception of sound in the brain of a subject such as an animal or human being. In one form, a system includes an implantable electrode array including a plurality of spaced apart micro-needles. The system also includes a first electrical lead electrically coupled to and extending from the implantable electrode array, and an auditory signal device configured to produce one or more electrical signals representative of communications received from an external processor. An interposer is configured to electrically couple the implantable electrode array and the auditory signal device in an arrangement where one or more electrical signals produced by the auditory signal device may be transmitted through the first electrical lead to the implantable electrode array. Various novel stimulation strategies can be employed, such as place modulated stimulation signals.
The present invention relates to the filed of immunotherapy, in particular, of lymphoproliferative disorders associated with abnormal proliferation of HLA-DR+ cells, e.g., malignancies of the hematopoietic and lymphoid tissues. The invention provides pharmaceutical compositions useful for, e.g., adoptive T cell therapy or T cell receptor (TCR) gene therapy or such disorders, as well as novel expression vectors, host cells and y8 (gamma/delta) TCR constructs. In particular, the inventors have identified γδ (gamma/delta) TCR constructs that can specifically bind to HLA-DR. In addition to host cells engineered to express such constructs that can be used for therapeutic as well as diagnostic purposes, soluble TCR constructs are provided, which can, e.g., be used in a method of detecting HLA-DR+ cells, e.g., in vitro as well as bispecific constructs that can be therapeutically used.
The present disclosure provides third-generation self-inactivating (SIN) lentiviral vectors comprising a nucleic acid sequence encoding MyoVIIa isoform 1 for treatment of Usher IB syndrome in a subject in need thereof. In some embodiments, treatment of Usher IB syndrome comprises amelioration of presbycusis caused by heterozygous mutations in MyoVIIa and/or balance problems caused by homozygous mutations in MyoVIIa.
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (Germany)
MEDIZINISCHE HOCHSCHULE HANNOVER (Germany)
Inventor
Sake, Svenja
Haid, Sibylle
Rückert, Jessica
Schulz, Thomas
Pietschmann, Thomas
Abstract
The invention pertains to the use of lonafarnib or any analog or derivative thereof for the treatment of a viral disease characterized by a viral entry into a host cell via a viral fusion glycoprotein (F-protein). In particular, the invention provides treatments of human respiratory syncytial virus (HRSV) caused diseases comprising the administration (use) of lonafarnib or its analogs or derivatives, as well as pharmaceutical compositions comprising lonafarnib or its analogs and derivates.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating and/or preventing cardiogenic shock. The present invention also relates to vectors comprising the nucleic acid, host cells expressing the nucleic acid, pharmaceutical compositions comprising said protein, nucleic acid, vector or host cell for use in treating and/or preventing cardiogenic shock, and to methods for treating and/or preventing cardiogenic shock. The present invention further relates to a method of preparing an animal model of cardiogenic shock, and to animals obtained by said method.
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating and/or preventing cardiogenic shock. The present invention also relates to vectors comprising the nucleic acid, host cells expressing 5 the nucleic acid, pharmaceutical compositions comprising said protein, nucleic acid, vector or host cell for use in treating and/or preventing cardiogenic shock, and to methods for treating and/or preventing cardiogenic shock. The present invention further relates to a method of preparing an animal model of cardiogenic shock, and to animals obtained by said method.
In vitro process for producing organoids from mammalian cells, the process comprising or the steps of cultivating pluripotent stem cells (PSC) in cell culture medium in a stirred tank bioreactor under conditions suitable for producing PSC aggregates, removing PSC aggregates suspended in cell culture medium from the bioreactor, and preferably in a flow channel, encapsulating PSC aggregates separately in biocompatible hydrogel to produce separate hydrogel- encapsulated PSC aggregates, incubating the hydrogel-encapsulated PSC aggregates in cultivation vessels under static conditions in medium containing at least one differentiation factor.
The present invention relates to a pharmaceutical composition comprising (i) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 14; and/or (ii) a compound promoting the expression and/or the activity of one or more5 long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 15 to 17.
The present invention relates to the field of testing for pyrogens, e.g., endotoxin/LPS, non-endotoxin pyrogen (NEP), process-related impurities or endogenous pyrogens. This is highly relevant, e.g., for quality testing and safety testing of pharmaceutical compositions. The invention provides a method of testing a composition for the presence of at least one pyrogen, comprising (i) incubating a human monocyte or macrophage population derived from pluripotent stem cells in vitro, e.g., a human CD45+/CD11b+/CD14+/CD34−/TRA1-60− monocyte population or CD45+/CD11b+/CD14+/CD34−/TRA1-60−/CD163+ macrophage population derived from pluripotent stem cells with said composition, and (ii) determining a reaction of the monocytes in the population to the presence of the at least one pyrogen, preferably, determining the quantity of an inflammatory cytokine expressed by the monocytes. The invention also provides the use of such monocyte populations for testing a composition for at least one pyrogen, in essence, the use of monocytes derived from pluripotent stem cells for a monocyte activation test (MAT), and kits suitable for this assay. The use of such stem-cell derived monocytes overcomes difficulties raised e.g., by variability of donor cells and allows for test systems that are reproducable and stable in the long term.
An apparatus dispenses a raw material in liquid form into a manufacturing zone. The raw material is, by computer-controlled, point-by-point targeted light irradiation, heated and solidified by the region of incidence of a light beam relative to the manufacturing zone being altered in a continuous and/or in a step-by-step manner. The light beam is emitted from the light beam source, or from an optical unit influencing the light of the light beam source, with a substantially ring-shaped light intensity profile. The ring-shaped light intensity profile is formed by a ring-shaped region in which the light intensity initially increases in the direction toward the center of the ring from the outer diameter and then drops off again toward the inner diameter of the ring, with the light intensity being equal to zero in the interior region of the ring.
B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
The invention provides a compound, for use as single compound or for use as a combination of at least two compounds, for use in the prevention and/or treatment of liver fibrosis and/or liver cirrhosis, e.g. as a pharmaceutically active compound for use in the prevention or treatment of liver fibrosis, which compound is an inhibitor of hyaluronan synthetase, or an inhibitor of integrin alpha-6.
The present invention relates to a fusion protein that provides for maintenance of regulatory T-cells that are polyclonal, e.g. natural isolated antigen-specific Treg cells, and/or Treg cells generated by introduction of a nucleic acid construct for expression of FOXP3, and/or Treg cells which express a chimeric antigen receptor (CAR), which Treg cells in contact with the cognate antigen are activated for suppressive activity, as well as to Treg cells that express the fusion protein, wherein the Treg cells are polyclonal or the Treg cells express a CAR. The fusion protein comprises or consists of an optional secretory leader peptide, IL-2, preferably a linker peptide, and a membrane-spanning anchor, which fusion protein is also termed membrane-bound IL-2.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
42.
HUMAN MESENCHYMAL STEM CELL-CONDITIONED MEDIUM AND HUMAN MESENCHYMAL STEM CELLS FOR USE IN TREATMENT OF CHRONIC HEART-LUNG AND VASCULAR DISEASES, IN PARTICULAR, OF PULMONARY ARTERIAL HYPERTENSION (PAH)
The present invention relates to the field of medical treatment of chronic disease with stem-cell derived products, in particular, human mesenchymal stem cell-derived treatment of chronic heart-lung and vascular diseases. The inventors provide human mesenchymal stem cell-conditioned medium, such as human umbilical cord mesenchymal stem cell-conditioned medium (HUMSC-CM) for use in treatment of chronic heart-lung and vascular diseases, in particular, pulmonary hypertension (PH, groups 1-5), such as pulmonary arterial hypertension (PAH; group 1 PH according to World Symposium on Pulmonary Hypertension 2018 ). The invention also provides a method of treating chronic heart-lung-vascular diseases by means of administering such conditioned medium intravascularily. Optionally, the treatment may additionally comprise administering human umbilical cord mesenchymal stem cells to the patient.
The invention provides an analytical method for detecting the level of activity of superoxide dismutase (SOD2, e.g. UniProtKB P04179 (SODM_HUMAN) and/or of UBR1 and/or of UBR2 in a sample originating from a patient for determining the sensitivity for, or resistance against, tumour treatment with L-asparaginase.
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61P 35/02 - Antineoplastic agents specific for leukemia
The present invention relates to a process for producing liver cells, especially liver stem cells, which after injection into a mammal or in vitro form liver cells that are differentiated, especially differentiated into hepatocytes, into cholangiocytes, and preferably also into liver sinusoidal endothelial cells (LSEC) that can e.g. form blood sinusoidal capillaries. The invention is based on in in vitro producing liver stem cells from a sample of liver tissue, cultivating the liver stem cells in vitro for an increase in cell number. It has been found that the liver stem cells that are produced by the process of the invention can be cultivated and increased in number while maintaining their capability to differentiate into liver cells, especially into hepatocytes, cholangiocytes, and preferably also into LSEC. Accordingly, the process of the invention is suitable for producing liver stem cells that are autologous for the originator of the sample of liver tissue.
A system includes a stent Including a first end for arrangement on a tubal ostium, a second end for arrangement on a bony isthmus of smaller diameter than a diameter of the first end, and adjacent to the second end a length portion of decreasing diameter. The system further includes an applicator for placement of the stent in a Eustachian tube. The applicator has a proximal end for handling the applicator and a distal end for receiving the stent. The distal end includes an inner part which has at least one area that is plastically deformable by manual force, for adaptation to a patient-dependent access angle of the Eustachian tube, and an outer tube which surrounds the inner part at a radial distance and which delimits an annular gap for receiving the stent, with the stent in the annular gap made of nitinol and being self-expanding.
The invention relates to a suction-flushing-system for a medical instrument having at least one optical device in a distal region adapted for insertion into a patient, which is cleanable by means of the suction-flushing-system. The invention also relates to a medical instrument having such a suction-flushing-system.
A61B 1/015 - Control of fluid supply or evacuation
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
47.
LONG NON-CODING RNA AS THERAPEUTIC TARGET IN CARDIAC DISORDERS AND CARDIAC REGENERATION
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The new alpharetrovirus-based particles are suitable for high efficiency of transiently transducing animal cells, e.g. human or murine cells, and which efficiently introduce coding and non-coding RNA contained in the alpharetrovirus-based particles into target cells The alpharetrovirus-based particles also provide for high efficiency of the activity and/or integrity of the RNA that is introduced into the animal cells, as the particles protect the incoming RNA from degradation during entry. The transferred RNA can be of non-coding nature (e.g. single guide (sg) RNA, short-hairpin (sh) RNA, micro RNA, or long non-coding (Inc) RNA, or the RNA may encode proteins or peptides, e.g. receptors, transcription factors, cellular enzymes, antigens for use in vaccination, gene/protein therapy and/or gene editing nucleases, recombinases and transposases.
TWINCORE, ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (Germany)
Inventor
Schambach, Axel
Kalinke, Ulrich
Bruhn, Matthias
Chiyyeadu, Abhishek
Abstract
The present invention relates to novel antibody-based binding composition with specificity for the SARS-CoV-2 spike receptor-binding domain, to a multispecific antibody-based binding composition with specificity for at least two different epitopes on the SARS-CoV-2 spike receptor-binding domain, to a nucleic acid encoding the antibody-based binding composition of the present invention, or the multispecific antibody-based binding composition of the present invention,.to a pharmaceutical composition comprising the antibody-based binding composition of the present invention, the multispecific antibody-based binding composition of the present invention, or the nucleic acid of the present invention, including for use in the prevention or treatment of an infection with SARS-CoV-2.
The invention relates to a patient-specific implant (5) for insertion into a body cavity of a patient, for example into the round window niche of the middle ear. The invention also relates to a method of manufacturing such an implant (5).
A61F 11/00 - Methods or devices for treatment of the ears or hearing sense Non-electric hearing aidsMethods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing senseProtective devices for the ears, carried on the body or in the hand
B33Y 50/00 - Data acquisition or data processing for additive manufacturing
B33Y 80/00 - Products made by additive manufacturing
51.
BIOMARKER PANEL FOR DIAGNOSING PULMONARY DYSFUNCTION
The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of a pulmonary dysfunction in a subject. The method is based on the determination of the level of a panel of biomarkers selected from TM4SF18, TRGV9, ADORA2A, H963, IRF2, TNFSF14, TRIB1, SMAD3, TSLP, SLAMF8, THBS1, SOD1, HAS2, TLR2, THBD, TRA, TFEC, SPHK1, COL3A1, Elastin, IL6R, SN, TEK, SOX7, CXCL9, CXCL10, SLC38A6, SLC15A3, TGFA, SLPI, VWF, TLR8, TGFB1, CXCR6, CCL24, PD1, PLA1A, TRD, CTLA4, MMP9, CD301, PDL1, PDL2, TGFB1, CXCR6, CCL24, PD1, PLA1A, TRD, CTLA4, MMP9, and CD301. The new biomarker panels of this invention allow diagnosing and even stratifying various pulmonary dysfunctions in a subject, and even allow early detection of Chronic lung allograft dysfunction (CLAD). Furthermore provided are diagnostic kits for performing the methods of the invention.
Immune cells containing a nucleic acid construct, also referred to as a vector or viral vector, for use in immune therapy, e.g. for use in the treatment of cancer, or for use in the treatment of autoimmune disease, or for use in the treatment of GvH or HvG. The nucleic acid construct comprises a second expression cassette for constitutive expression of a CAR or a TCR, the binding of which to its target antigen results in signalling and induces the expression of an effector molecule from a first expression cassette, which is contained on the same nucleic acid construct, and which first expression cassette encodes the effector molecule under the control of a promoter inducible by signalling of the CAR or TCR.
The invention relates to a medical insertion system with an insertion device for inserting a medical device attached to the insertion device into a body region of a patient, wherein the insertion device has at least one force sensor for detecting a force transmitted from the medical device to the insertion device in a measuring direction, the insertion system having an evaluation unit for evaluating a force signal which is emitted by the force sensor and represents the force detected by the force sensor.
The invention provides a viral vector particle based on AAV2, which in its capsid protein (CAP) contains an inserted amino acid section which confers tropism for cardiomyocytes.
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating or preventing fibrosis and hypertrophy. The present invention also relates to the protein MYDGF or nucleic acids encoding said protein for use in treating heart failure. The present invention also relates to vectors comprising the nucleic acid, host cells expressing the nucleic acid, and methods for use in treating fibrosis and hypertrophy, and for use in treating heart failure.
An accessory kit is provided for interventional procedures using a magnetic resonance imaging scanner. The accessory kit includes a patient support and an electrical connection adapter. The patient support has a first end proximal and a second end distal to the scanner. The distal end is configured to create a space to accommodate a clinician, such as narrowing of the distal end or at least one cutout on a side of the distal end. The electrical connection adapter interfaces with the scanner and a scanner table. The accessory kit is configured so that when the proximal end is extended into the scanner bore, the distal end extends outside the bore. The narrowed width and/or cutout(s) of the exposed distal end and the extended gap between the scanner and scanner table create space on at least one side of the patient support that a clinician may use to access a patient.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 6/04 - Positioning of patientsTiltable beds or the like
H01R 31/06 - Intermediate parts for linking two coupling parts, e.g. adapter
57.
MRI/CT-COMPATIBLE REMOTE-CONTROLLED MICROPOSITIONING SYSTEM
The invention relates to a positioning device for positioning a medical instrument in relation to a patient. The positioning device comprises an attachment element designed to attach the positioning device to the patient and an instrument holding element designed to hold the medical instrument, the attachment element having a holding surface for contact with the patient.
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61B 90/17 - Fixators for body parts, e.g. skull clampsConstructional details of fixators, e.g. pins for soft tissue, e.g. breast-holding devices
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (France)
UNIVERSITE PARIS CITE (France)
APHP - ASSISTANCE PUBLIQUE - HOPITAUX PARIS (France)
UNIVERSITE DE LIMOGES (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE LIMOGES (France)
Inventor
Callemeyn, Jasper
Nava, Josue
Deutsch, Andreas
Hatzikirou, Haralampos
Anglicheau, Dany
Marquet, Pierre
Gwinner, Wilfried
Naesens, Maarten
Abstract
The invention relates to in vitro methods of distinguishing between ABMR and TCMR in an individual at risk of a kidney transplant rejection, or having any type of kidney transplant rejection, the method comprising the steps of :a) determining in a biopsy of said individual the expression level of at least two genes of a first set of genesand determining in said biopsy of said individual the expression level of at least two genes of a second set of genes b) comparing the expression levels of said at least 2 genes of the first set and said at least 2 genes of the second set with their expression level in a reference biopsy of a healthy individual with a kidney transplant.Figure 7.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
59.
TCR-INDEPENDENT MOLECULAR IDENTIFICATION OF MUTATION-RELATED AND TUMOR-SPECIFIC T CELLS
The present invention relates to the field of tumor immunology. It provides a method for identifying mutation-related human CD8+ T cells, in particular, tumor-specific T cells of a human subject, comprising analyzing CD8+ T cells of the subject by analysing the expression of at least one marker selected from a first group consisting of CD82, CD194, CD244, CD28, CD62L and CD55, and preferably, a marker selected from a second group comprising CD11a or CD18 or CD43. A preferred marker for mutation-related CD8+ T cells is CD82, which may be analysed in combination, e.g., with CD11a. Without the need to identify any epitope to which T cells reacts, this method can advantageously be used to isolate the entire individual pool of mutation-related T cells, and, optionally, to identify the sequence of a mutation-related TCR, which allows for generation of transgenic T cells expressing the TCR. Compositions substantially comprising tumor-specific CD82hiCD8+ T cells and/or CD194hi, CD244−, CD28+, CD62L+ and/or CD55+ CD82hi CD8+ T cells can be used for treatment of a cancer patient, e.g., by adoptive T cell transfer. The method of the invention can also be used for diagnostic purposes to identify human mutation-related T cells or diagnosing a tumor disease or for testing responses of a cancer patient to an immune stimulatory therapy, preferably, a therapy with a checkpoint inhibitor.
The invention provides retroviral envelope glycoproteins in which the cytoplasmic C-terminal tail (CTT) from N-terminus to C-terminus comprises or consists of a T-domain and an R- domain, wherein the R-domain is truncated from its C-terminus, and hybrid glycoproteins and retroviral, especially alpharetroviral, lentiviral or gammaretroviral vector particles containing the glycoprotein. The glycoproteins target the SLC1A5 receptor for target cell entry.
The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/00 - Drugs for disorders of the cardiovascular system
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
62.
LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/00 - Drugs for disorders of the cardiovascular system
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
63.
HLA-DR-SPECIFIC GAMMA DELTA TCR CONSTRUCTS AND USE THEREOF
The present invention relates to the filed of immunotherapy, in particular, of lymphoproliferative disorders associated with abnormal proliferation of HLA-DR+ cells, e.g., malignancies of the hematopoietic and lymphoid tissues. The invention provides pharmaceutical compositions useful for, e.g., adoptive T cell therapy or T cell receptor (TCR) gene therapy or such disorders, as well as novel expression vectors, host cells and y8 (gamma/delta) TCR constructs. In particular, the inventors have identified γδ (gamma/delta) TCR constructs that can specifically bind to HLA-DR. In addition to host cells engineered to express such constructs that can be used for therapeutic as well as diagnostic purposes, soluble TCR constructs are provided, which can, e.g., be used in a method of detecting HLA-DR+ cells, e.g., in vitro as well as bispecific constructs that can be therapeutically used.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The invention provides an analytical method for detecting bladder cancer by analysing a urine sample for presence of a glycan tumour antigen, the presence of which has been identified to indicate bladder cancer. The analytical method has the advantage that the tumour antigen can be analysed in a urine sample and has a high accuracy for indicating presence of cancer in the urinary tract, especially bladder cancer, e.g. the method has a low rate of false positive results.
HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH (Germany)
Inventor
Klos, Andreas
Laudeley, Robert
Hegemann, Johannes H.
Guzmán, Carlos Alberto
Ebensen, Thomas
Wintgens, Sebastian
Abstract
The present invention relates in a first aspect to an immunogenic composition comprising at least three Chlamydia ssp. surface antigens selected from the group of PmpA, PmpD, PmpG, PmpH and antigen Ctad1. Further, the present invention relates to the immunogenic composition comprising CDN as adjuvant, in particular, c-diAMP. Moreover, a pharmaceutical composition comprising the immunogenic composition according to the present invention is provided as well as a vaccine comprising said immunogenic composition. The vaccine is particularly useful in eliciting an immune response against Chlamydia ssp. in an animal, including a human, in particular, for use in treating or preventing the infection by Chlamydia ssp. The vaccine, pharmaceutical composition or immunogenic composition may be administered mucosally, preferably is administered at least three times.
The invention provides a process for producing acellular implants from a matrix material of non- human animal origin by decellularizing a matrix material to generate an acellular matrix, oxidizing the acellular matrix by treatment of the acellular matrix with an oxidant, to generate an oxidized acellular matrix, and reacting the oxidized acellular matrix with an agent that is reactive with carbonyl groups and is non-antigenic.
TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (Germany)
MEDIZINISCHE HOCHSCHULE HANNOVER (Germany)
Inventor
Sake, Svenja
Haid, Sibylle
Rückert, Jessica
Schulz, Thomas
Pietschmann, Thomas
Abstract
The invention pertains to the use of lonafarnib or any analog or derivative thereof for the treatment of a viral disease characterized by a viral entry into a host cell via a viral fusion glycoprotein (F-protein). In particular, the invention provides treatments of human respiratory syncytial virus (HRSV) caused diseases comprising the administration (use) of lonafarnib or its analogs or derivatives, as well as pharmaceutical compositions comprising lonafarnib or its analogs and derivates.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention provides a combination of compositions comprising in a first composition 17β-estradiol as the active ingredient and, as a second composition, a suspension of cells for use in the treatment of functional defects of an epithelium, e.g. of an epithelium of a tissue, which tissue may be part of an organ.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
70.
METHOD FOR COATING A MEDICAL DEVICE AND COATED MEDICAL DEVICE
The present invention relates in a first aspect to a method for coating a medical device suitable for implantation into an individual or for application on skin or mucosal tissue of an individual. Said method comprises the steps of applying to at least a portion of the surface of said device a coating layer whereby said coating layer comprises commensal microorganisms, like commensal bacteria, to form a biofilm on the at least portion of the surface of said medical device, further comprising the step of drying the biofilm coated on the surface of said medical device whereby the commensal microorganisms are eventually killed in case they were not applied as killed microorganisms in the step above, for obtaining a medical device having at least a portion of its surface coated with non-living commensal microorganisms In a further aspect, the coated medical devices obtainable by the method according to the present invention are provided. The coated medical devices according to the present invention are particularly useful in applications being mucosal tissue or a skin of an individual, like for use as an implant for dental use in the oral cavity. Finally, the present invention relates to the use of commensal bacteria like Streptococcus oralis for coating a medical device suitable for use as an implant into an individual or for application on skin or mucosal tissue of an individual.
A signalling molecule and an immune cell expressing the signalling molecule for use in the treatment of an undesired immune activity, which signalling molecule is a fusion protein which comprises a ligand domain, a spacer, a transmembrane domain, and at least one intracellular signalling domain, wherein the ligand domain comprises at least one epitope or all of the epitopes of the cognate antigen, or the cognate antigen, which cognate antigen is the target of the undesired immune activity.
The present invention relates to the field of gene therapy for the treatment of sensorineural hearing loss. In particular, the invention discloses a composition comprising a 3rdgeneration lentiviral vector pseudotyped with a viral envelope glycoprotein capable of binding to a receptor expressed in a cell of the inner ear for use in the treatment or prevention of sensorineural hearing loss, wherein said composition has a viral titer of at least 107TU/mL and is administered to the inner ear of a subject suffering from or in danger to undergo sensorineural hearing loss. The viral envelope glycoprotein is capable of binding to a receptor selected from the group consisting of the LDL-receptor and LDL-R family members, the SLC1 A5-receptor, the Pit1 /2-receptor and the PIRYV-G-receptor. Preferably, the viral glycoprotein is MARAV-G, COCV-G, VSV-G, VSV-G ts or PIRYV-G, most preferably, MARAV-G. The lentiviral vector further comprises a cargo sequence comprising, e.g. a protein-coding gene, a miRNA, an shRNA, a IncRNA or an sgRNA, wherein expression of said cargo sequence in the cell of the inner ear is capable of reducing, eliminating or preventing at least a symptom of sensorineural hearing loss in the subject. The invention further discloses a method for treating sensorineural hearing loss in a subject in need thereof.
The present invention relates to the field of testing for pyrogens, e.g., endotoxin /LPS, non- endotoxin pyrogen (NEP), process-related impurities or endogenous pyrogens. This is highly relevant, e.g., for quality testing and safety testing of pharmaceutical compositions. The invention provides a method of testing a composition for the presence of at least one pyrogen, comprising (i) incubating a human monocyte or macrophage population derived from pluripotent stem cells in vitro, e.g., a human CD45+/CD11b+/CD14+/CD34-/TRA1-60-monocyte population or CD45+/CD11b+/CD14+/CD34-/TRA1-60-/CD163+ macrophage population derived from pluripotent stem cells with said composition, and (ii) determining a reaction of the monocytes in the population to the presence of the at least one pyrogen, preferably, determining the quantity of an inflammatory cytokine expressed by the monocytes. The invention also provides the use of such monocyte populations for testing a composition for at least one pyrogen, in essence, the use of monocytes derived from pluripotent stem cells for a monocyte activation test (MAT), and kits suitable for this assay. The use of such stem-cell derived monocytes overcomes difficulties raised e.g., by variability of donor cells and allows for test systems that are reproducable and stable in the long term.
The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
75.
FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE
A fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
76.
Fusion protein for use in the treatment of HVG disease
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an implant suitable for nerve regeneration, also referred to as a neural implant, that is especially suitable for bridging defect sites of nerves, especially defect sites within the central nervous system, e.g. for spanning or bridging defects of axons within the spinal cord, which implant comprises or consists of a sheath, which preferably about its axis is circumferentially closed between its ends, the sheath consisting of fibrin and silk fibers arranged in axial direction inside the sheath, optionally fibrin that fills the inner volume of the sheath, e.g. fibrin filling the inner volume of the sheath and between the silk fibers.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
MEDIZINISCHE HOCHSCHULE HANNOVER (Germany)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE LIMOGES (France)
LE CENTRE HOSPITALIER ET UNIVERSITAIRE DE LIMOGES (France)
Inventor
Naesens, Maarten
Van Loon, Elisabet
Marquet, Pierre
Gwinner, Wilfried
Anglicheau, Dany
Essig, Marie
Gazut, Stephane
Abstract
The invention relates to methods for diagnosing or determining in a subject who underwent a solid organ transplantation the risk of developing graft rejection other than T cell mediated, comprising the steps of: measuring in a peripheral blood sample from said subject the RNA expression levels of a set of genes comprising at least CXCL10, FCGR1A, FCGR1B and TEMP1; determining from the measured expression levels of said set of genes, an expression profile; comparing the determined expression profile of said subject with a reference expression profile; and determining from said comparison, whether said subject is experiencing said rejection or has an increased risk of developing said rejection.
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
UNIVERSITÉ PARIS CITÉ (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
FONDATION IMAGINE (France)
UNIVERSITÉ D'EVRY-VAL-D'ESSONNE (France)
MEDIZINISCHE HOCHSCHULE HANNOVER (Germany)
GENETHON (France)
Inventor
Andre, Isabelle
Six, Emmanuelle
Bellier, Florence
Delville, Marianne
Cavazzana, Marina
Amendola, Mario
Schambach, Axel
Abstract
IPEX (Immune dysregulation Polyendocrinopathy X linked) syndrome is a primary immunodeficiency caused by mutations in the gene encoding the transcription factor forkhead box P3 (FOXP3), which leads to the loss of function of thymus-derived CD4+CD25+ regulatory T (tTreg) cells. Preclinical and clinical studies suggest that T cell gene therapy approaches designed to selectively restore the repertoire of Treg cells by transfer of wild type FOXP3 gene is a promising potential cure for IPEX. However, there is still a need for a vector that can be used efficiently for the preparation of said Treg cells. The inventors thus compared 6 different lentiviral constructs according to 4 criteria (vector titers, level of transduction of human CD4+ T cells, level of expression of FOXP3 and ΔLNGFR genes, degree of correlation between both expression) and selected one construct comprising a bidirectional PGK-EF1a promoter that showed remarkable efficiency.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
The present invention relates to a process for producing liver cells, especially liver stem cells, which after injection into a mammal or in vitro form liver cells that are differentiated, especially differentiated into hepatocytes, into cholangiocytes, and preferably also into liver sinusoidal endothelial cells (LSEC) that can e.g. form blood sinusoidal capillaries. The invention is based on in vitro producing liver stem cells from a sample of liver tissue, cultivating the liver stem cells in vitro for an increase in cell number. It has been found that the liver stem cells that are produced by the process of the invention can be cultivated and increased in number while maintaining their capability to differentiate into liver cells, especially into hepatocytes, cholangiocytes, and preferably also into LSEC. Accordingly, the process of the invention is suitable for producing liver stem cells that are autologous for the originator of the sample of liver tissue.
The invention relates to an applicator (1) for placing a stent in a eustachian tube, having the following features: the applicator (1) has a proximal end for handling the applicator (1) and a distal end (7) for receiving a stent which can be placed in a eustachian tube. The distal end (7) has an inner part (9) and an outer tube (6) which surrounds the inner part (9) at a radial distance thereto and delimits an annular gap (10) for receiving the stent. The inner part (9) is designed to be plastically deformable at least in some regions in order to adapt to a patient-dependent tube angle of the eustachian tube, and the stent consists of nitinol and has an elongated conical section.
A61F 2/962 - Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve
A61F 11/00 - Methods or devices for treatment of the ears or hearing sense Non-electric hearing aidsMethods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing senseProtective devices for the ears, carried on the body or in the hand
A61F 2/94 - Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
Adenovirus for use in anti-tumour therapy which has specificity for tumour cells, especially for tumour cells that have reduced activity levels of the tumour suppressor p53. It is known that the majority of tumours characteristically exhibit reduced activity of the tumour repressor p53. In tumour-bearing patients, the adenovirus provides for an effective cross-presentation of tumour antigens, which can be neoantigens, e.g. having low immunogenicity, and hence supports the induction of tumour-specific immune cells, especially of tumour-specific CD8 T- cells. Further, the adenovirus in tumour patients stimulates the non-specific immune response by NK-cells, preferably both locally and systemically, and the adenovirus improves migration of immune cells, e.g. T-cells, NK-cells, and antigen-presenting cells (APC), e.g. dendritic cells, into the tumour, and the adenovirus improves the maturation of immune cells, especially of APC, and improves the cytolysis of tumour cells by immune cells. The adenovirus has an E4 protein which contains an E4 orf4-encoded protein of one of amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.
An in vitro process for producing megakaryocytes, and optionally platelets from the megakaryocytes, including the steps of cultivating stem cells, e.g. induced pluripotent stem cells, to generate aggregated pluripotent stem cells, preferably cultivating the aggregates in suspension in medium, inducing differentiation in these aggregates, and isolating megakaryocytes from the culture medium.
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaft E.V. (Germany)
Medizinische Hochschule Hannover (Germany)
Inventor
Fühner, Viola
Hust, Michael
Dübel, Stefan
Löffler, Felix
Gerhard, Ralf
Abstract
The invention provides an antigenic peptide comprising an epitope for use in the prevention and/or treatment of an infection by C. difficile, e.g. for use as a vaccine in the prevention and/or treatment of an infection by C. difficile, and protective antibodies directed against the epitope.
The invention provides a viral vector particle based on AAV2, which in its capsid protein (CAP) contains an inserted amino acid section which confers tropism for cardiomyocytes.
HELMHOLTZ ZENTRUM MÜNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (Germany)
Inventor
Stripecke, Renata
Slabik, Constanze
Zeidler, Reinhard
Hammerschmidt, Wolfgang
Abstract
An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR includes an extracellular antigen-binding domain, including an antibody or antibody fragment that binds to a protein encoded by a herpes virus, or to a protein complex including the protein (herpes virus antigen), wherein the herpes virus antigen is present on the surface of a human cell that is latently infected with said herpes virus and supports the lytic phase of viral replication. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of the cell in the treatment of a medical disorder associated with human herpesvirus, such as herpes virus-associated cancers, chronic active herpes virus infections or primary herpes virus infections. In preferred embodiments the herpes virus is Epstein-Barr virus (EBV) and a preferred herpes virus antigen target of the CAR is the EBV glycoprotein 350/220 (gp350/gp220).
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating or preventing fibrosis and hypertrophy. The present invention also relates to the protein MYDGF or nucleic acids encoding said protein for use in treating heart failure. The present invention also relates to vectors comprising the nucleic acid, host cells expressing the nucleic acid, and methods for use in treating fibrosis and hypertrophy, and for use in treating heart failure.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
90.
ACCESSORY KIT FOR INTERVENTIONAL PROCEDURES USING MAGNETIC RESONANCE IMAGING
An accessory kit is provided for interventional procedures using a magnetic resonance imaging scanner. The accessory kit includes a patient support and an electrical connection adapter. The patient support has a first end proximal and a second end distal to the scanner. The distal end is configured to create a space to accommodate a clinician, such as narrowing of the distal end or at least one cutout on a side of the distal end. The electrical connection adapter interfaces with the scanner and a scanner table. The accessory kit is configured so that when the proximal end is extended into the scanner bore, the distal end extends outside the bore. The narrowed width and/or cutout(s) of the exposed distal end and the extended gap between the scanner and scanner table create space on at least one side of the patient support that a clinician may use to access a patient.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 6/04 - Positioning of patientsTiltable beds or the like
G01R 33/20 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education, entertainment and sport services; Publishing, reporting, and writing of texts; Education and instruction services; Organisation of conferences, exhibitions and competitions; Organisation and holding of fairs for cultural or educational purposes; Organising events for cultural purposes; Exhibiting of animals; Providing cultural activities; Exhibiting of animals; Organisation of Webinars; Providing on-line electronic publications, not downloadable; Providing electronic publications; Providing on-line publications; Providing online electronic publications, not downloadable; Provision of information relating to publishing; Providing on-line electronic publications, not downloadable; Providing on-line non-downloadable general feature magazines; Providing on-line electronic publications, not downloadable; Publication of the results of clinical trials; Publication of educational and training guides; Publishing of scientific papers; Publication of material which can be accessed from databases or from the internet; Publishing of journals, books and handbooks in the field of medicine; Publication of medical texts; Publication of prospectuses; Publishing scientific papers in relation to medical technology; Education services relating to the veterinary profession; Organization of educational congresses; Arranging of conventions for training purposes; Conducting of seminars and congresses; Arranging and conducting of congresses; Arranging, conducting and organisation of congresses; Arranging and conducting of conferences and congresses; Arranging and conducting of conferences, congresses and symposiums; Arranging and conducting of symposiums; Arranging, conducting and organisation of symposiums; Organisation of conferences and symposia in the field of medical science; Organisation of seminars; Organisation of seminars; Seminars; Organisation of seminars and conferences; Arranging, conducting and organisation of seminars; Organization of seminars and conventions in the field of medicine; Arranging of workshops; Arranging and conducting of workshops [training]; Arranging and conducting of workshops [training]; Conducting courses, seminars and workshops; Arranging and conducting of colloquiums; Arranging and conducting of colloquiums; Consultancy and information services relating to arranging, conducting and organisation of colloquiums. Science and technology services; Analytical laboratory services; Analytical laboratory services; Consultancy in the field of scientific research; Consultancy services in the field of technological development; Advisory services relating to technological research; Advisory services relating to scientific research; Advisory services relating to scientific instruments; Provision of information relating to technological research; Providing scientific research information and results from an online searchable database; Research laboratories; Technical research; Technical data analysis services; Conducting of technical feasibility studies; Technical research projects and studies, Especially, in relation to the following fields, Animal experiments; Conducting technical project studies; Technological research; Conducting technical project studies; Technological analysis services; Analytical laboratory services; Laboratory testing; Measurement services; Scientific testing services; Development of measuring probes for biotechnological applications; Compilation of scientific information; Preparation of scientific reports; Provision of information relating to scientific research; Provision of scientific information; Research services, Development services, Especially, in relation to the following fields, Animal experiments; Research and development in the field of biotechnology; Provision of research services; Laboratory services for analytical testing; Research laboratories; Medical and pharmacological research services; Natural science services; Technological consultancy; Technological services, Research relating thereto, Scientific research, Especially, in relation to the following fields, Animal experiments; Scientific services; Veterinary laboratory services; Scientific design services; Scientific research; Scientific services and research relating thereto, Especially, in relation to the following fields, Animal experiments; Provision of information and data relating to medical and veterinary research and development, Especially, in relation to the following fields, Animal experiments; Biomedical research services; Research and development services in the field of immunology; Scientific research relating to biology. Veterinary advisory services; Animal healthcare services; Providing veterinary information; Veterinary information services provided via the Internet; Veterinary services (Professional consultancy relating to -); Providing information relating to veterinary services; Animal healthcare services; Animal grooming services; Animal grooming services.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education, entertainment and sport services; Publishing, reporting, and writing of texts; Education and instruction services; Organisation of conferences, exhibitions and competitions; Organisation and holding of fairs for cultural or educational purposes; Organising events for cultural purposes; Exhibiting of animals; Providing cultural activities; Exhibiting of animals; Organisation of Webinars; Providing on-line publications (not downloadable); Providing electronic publications; Providing on-line publications; Providing online electronic publications, not downloadable; Provision of information relating to publishing; Providing on-line publications (not downloadable); Providing on-line non-downloadable general feature magazines; Providing non-downloadable electronic publications from a global computer network or the Internet; Publication of the results of clinical trials; Publication of educational and training guides; Publishing of scientific papers; Publication of material which can be accessed from databases or from the internet; Publishing of journals, books and handbooks in the field of medicine; Publication of medical texts; Publication of prospectuses; Publishing scientific papers in relation to medical technology; Education services relating to the veterinary profession; Organization of educational congresses; Arranging of conventions for training purposes; Conducting of seminars and congresses; Arranging and conducting of congresses; Arranging, conducting and organisation of congresses; Arranging and conducting of conferences and congresses; Arranging and conducting of conferences, congresses and symposiums; Arranging and conducting of symposiums; Arranging, conducting and organisation of symposiums; Organisation of conferences and symposia in the field of medical science; Organisation of seminars; Organisation of seminars; Seminars; Organisation of seminars and conferences; Arranging, conducting and organisation of seminars; Organization of seminars and conventions in the field of medicine; Arranging of workshops; Arranging and conducting of workshops [training]; Arranging and conducting of workshops [training]; Conducting courses, seminars and workshops; Arranging and conducting of colloquiums; Arranging and conducting of colloquiums; Consultancy and information services relating to arranging, conducting and organisation of colloquiums. Science and technology services; Analytical laboratory services; Analytical laboratory services; Consultancy in the field of scientific research; Consultancy services in the field of technological development; Advisory services relating to technological research; Advisory services relating to scientific research; Advisory services relating to scientific instruments; Provision of information relating to technological research; Providing scientific research information and results from an online searchable database; Research laboratories; Technical research; Technical data analysis services; Conducting of technical feasibility studies; Technical research projects and studies, Especially, in relation to the following fields, Animal experiments; Conducting technical project studies; Technological research; Conducting technical project studies; Technological analysis services; Analytical laboratory services; Laboratory testing; Measurement services; Scientific testing services; Development of measuring probes for biotechnological applications; Compilation of scientific information; Preparation of scientific reports; Provision of information relating to scientific research; Provision of scientific information; Research services, Development services, Especially, in relation to the following fields, Animal experiments; Research and development in the field of biotechnology; Provision of research services; Laboratory services for analytical testing; Research laboratories; Medical and pharmacological research services; Natural science services; Technological consultancy; Technological services, Research relating thereto, Scientific research, Especially, in relation to the following fields, Animal experiments; Scientific services; Veterinary laboratory services; Scientific design services; Scientific research; Scientific services and research relating thereto, Especially, in relation to the following fields, Animal experiments; Provision of information and data relating to medical and veterinary research and development, Especially, in relation to the following fields, Animal experiments; Biomedical research services; Research and development services in the field of immunology; Scientific research relating to biology. Veterinary advisory services; Animal healthcare services; Providing veterinary information; Veterinary information services provided via the Internet; Veterinary services (Professional consultancy relating to -); Providing information relating to veterinary services; Animal healthcare services; Animal grooming services; Animal grooming services.
93.
STEM-CELL DERIVED MYELOID CELLS, GENERATION AND USE THEREOF
The present invention relates to stem-cell derived hematopoietic cells, in particular, myeloid cells, preferably, macrophages, their generation and use. In particular, the invention relates to a method of producing hematopoietic, preferably, myeloid cells, comprising cultivating embryoid bodies, which are, e.g., derivable from pluripotent stem cells such as induced pluripotent stem cells (iPSC), in suspension culture, to produce myeloid cell forming complexes, which are further cultivated in suspension culture to produce myeloid cells such as macrophages. This allows for a scalable and continuous production, e.g., in industry-compatible stirred tank bioreactors. Macrophages, e.g., macrophages produced with this method that have unique characteristics, can be used in pharmaceutical compositions for treatment of patients, e.g., for treatment of infection such as bacterial infection. The invention further provides application systems suitable for spraying, comprising myeloid cells such as macrophages, which can have a reduced size, for use in treatment of patients for treatment of infection, e.g., bacterial infection or wound healing.
C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells
C12N 5/078 - Cells from blood or from the immune system
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A method for processing CT imaging data includes providing CT imaging data obtained at two x-ray energy levels in a first respiratory phase, preferably in an inhalation phase, of the subject and providing second CT imaging data obtained at two x-ray energy levels in a second respiratory phase, preferably in an exhalation phase, of the subject. The method may include reconstructing first regional perfusion blood volume (PBV) imaging data from the provided first CT imaging data, reconstructing second regional PBV imaging data from the provided second CT imaging data, reconstructing first virtual non-contrast (VNC) imaging data from the provided first CT imaging data, reconstructing second VNC imaging data from the provided second CT imaging data, determining a transformation function for registering the first and second reconstructed VNC imaging data, and registering the first and second reconstructed VNC imaging data by applying the transformation function.
The present invention relates to adeno-associated virus capsid polypeptide sequences and their use in therapeutic transgene delivery to the eye and potentially other tissues.
The present invention relates to an analytical in vitro process for predicting the therapeutic effectiveness of at least one pharmaceutical compound in the treatment of leukemia and/or lymphoma, the process analysing the transmembrane potential of mitochondria in cells isolated from a patient by quantification of fluorescence emitted from a dye indicating induction of apoptosis.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
97.
TCR-INDEPENDENT MOLECULAR IDENTIFICATION OF MUTATION-RELATED AND TUMOR-SPECIFIC T CELLS
The present invention relates to the field of tumor immunology. It provides a method for identifying mutation-related human CD8+ T cells, in particular tumor-specific T cells of a human subject, comprising analyzing CD8+ T cells of the subject by analysing the expression of at least one marker selected from a first group consisting of CD82, CD194, CD244, CD28, CD62L and CD55, and preferably a marker selected from a second group comprising CD11a, CD18 or CD43. A preferred marker for mutation-related CD8+ T cells is CD82, which may be analysed in combination with CD11a, CD18 or CD43. Without the need to identify any epitope to which T cells reacts, this method can advantageously be used to isolate the entire individual pool of mutation-related T cells, and, optionally, to identify the sequence of a mutation-related TCR, which allows for generation of transgenic T cells expressing the TCR. Compositions substantially comprising tumor-specific T cells that are (i) CD8 +, (ii) either CD82 hi, CD194 hi, CD244 -, CD28 +, CD62L +and/or CD55 +and (iii) CD11a hi, CD18 hiand/or CD43 hi can be used for treatment of a cancer patient, e.g., by adoptive T cell transfer. The method of the invention can also be used for diagnostic purposes to identify human mutation-related T cells or diagnosing a tumor disease or for testing responses of a cancer patient to an immune stimulatory therapy, preferably, a therapy with a checkpoint inhibitor.
The present invention relates to a pharmaceutical composition comprising a compound promoting the expression and/or the activity of the non-coding RNA (ncRNA) of SEQ ID NO: 1 or a sequence being at least 85% identical thereto.
The present invention relates to a pharmaceutical combination of compositions for use in the treatment or prevention of a disease having cells bearing a target antigen as a vaccine and to a method for vaccination of a mammal, especially of a human for raising a cellular immune response directed against cells of the mammalian recipient, especially human recipient, which cells express a target antigen. The target antigen can e.g. be an autoantigen like a malignant antigen, i.e. a tumour-specific antigen. The pharmaceutical combination of compositions comprises a first composition and a second composition, wherein the second composition is for administration to recipient subsequent to the administration of the first composition, e.g. 2 to 10 days after the first composition. The pharmaceutical combination of compositions has the advantage of raising an effective antigen-specific T-cell response against cells bearing a target antigen that can be a malignant autoantigen, e.g. for raising an antigen-specific T-cell response against cells bearing a tumour-antigen. A further advantage is that the pharmaceutical combination of compositions can raise an antigen-specific T-cell response within a comparatively short time.
The invention relates to a prosthesis for implantation into a living body in the form of a magnetic artificial joint, in particular an artificial shoulder joint, comprising: a) a first prosthesis member comprising a socket member, b) a second prosthesis member comprising a head member, c) one of the socket member and the head member is at least partially composed as a permanent magnet and the other one of the socket member and the head member is at least partially composed of a magnetic material, or the socket member and the head member are both at least partially composed as a permanent magnet, d) the socket member comprises a recess on a surface side to be coupled with the head member, the recess comprising a concavely contoured contact surface, e) the head member comprises a projection on a surface side to be coupled with the socket member, the projection comprising a convexly contoured contact surface, f) the convexly contoured contact surface is adapted to the concavely contoured contact surface, such that the head member can be coupled in a rotatably jointed manner to the socket member in the nature of a ball/ball-socket joint, g) wherein the convexly contoured contact surface can perform a generally slip-fee rolling motion or a combined slipping and rolling motion on the concavely contoured contact surface in reaction to a change of an angle between the first and the second prosthesis member, and the convexly contoured contact surface can be shifted across the concavely contoured contact surface within a shifting area.
